|
| Friday, 29 January 2021, 08:00 HKT/SGT | |
| |
|
|
|
|
| The research demonstrated that the OX40 design enhanced the antitumor activity of CAR-T cells with the potential to overcome the challenge of treating solid tumors |
HONG KONG, Jan 29, 2021 - (ACN Newswire) - China Biotech Services Holdings Limited ("CH BIOTECH SER" or "Company", stock code: 8037.HK) non-wholly-owned subsidiary Shanghai Longyao Biotechnology Co., Ltd. ( "Shanghai Longyao"), the Chief Scientist Professor Xuanming Yang published a CD20-CART-OX40 related research article on January 27, 2021, EST, on Science Translational Medicine. Professor Yang found that an independently expressed full-length OX40 not only enhanced the cytotoxicity of CAR-T cells, it also reduced the exhaustion markers, thereby maintaining their function in immunosuppressive tumor microenvironment. In mouse tumor models and in patients with metastatic lymphoma, these CAR-T cells exhibited robust amplification and antitumor activities. The findings provide an alternative option for CAR-T optimization with the potential to overcome the challenge of treating solid tumors.
LY007 Cellular Injection is a chimeric antigen receptor T-cell (CAR-T) injection and is mainly used in the treatment of relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and metastatic follicular lymphoma. LY007 Cellular Injection has been developed independently by Shanghai Longyao and incorporates its patented OX40 co-stimulatory signal design. Experiments have proved that the design enhances the efficacy of the Product without compromising safety. According to the clinical trial application of LY007 Cellular Injection, Shanghai Longyao will commence Phase I clinical trial and study of LY007 Cellular Injection based on the submitted proposal. On January 21, 2021, the National Medical Products Administration's approval of Shanghai Longyao's clinical trial application for LY007 Cellular Injection demonstrates Shanghai Longyao's capabilities in the research and development of immunocellular drugs.
For further information about the CD-20-CART-OX40 related research article of Professor Yang Xiaoming, please visit the website of Science Translational Medicine https://stm.sciencemag.org/content/13/578/eaba7308
Topic: Press release summary
Sectors: Daily Finance, Daily News, BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| |
Latest Press Releases
TransNusa Focuses on Organic Growth to Strengthen Network Connectivity in China
Aug 11, 2025 23:55 HKT/SGT
|
|
|
Campaign to promote Hong Kong's advantages in professional services in Vietnam
Aug 11, 2025 22:46 HKT/SGT
|
|
|
Shoucheng-Backed Data Center REITs Surge on Market Debut
Aug 11, 2025 22:43 HKT/SGT
|
|
|
31 Concept to Debut Patent-Pending Technology at ISS Asia 2025 in Singapore
Aug 11, 2025 22:42 HKT/SGT
|
|
|
Everest Medicines Announces Full Approval of NEFECON(R) in Taiwan
Aug 11, 2025 22:39 HKT/SGT
|
|
|
Singapore's Digital Finance Model in Focus at the BFSI IT Summit - Singapore 2025
Aug 11, 2025 18:26 HKT/SGT
|
|
|
WRC 2025: Shoucheng Showcases Full Robotics Value Chain
Aug 11, 2025 16:27 HKT/SGT
|
|
|
Cryofocus Medtech Achieves Record Interim Results with 162% Revenue Surge Driven by Respiratory Intervention Products
Aug 11, 2025 10:41 HKT/SGT
|
|
|
Natural Beauty 2025 Interim Profit Surges by 136% to HK$11 Million 
Aug 11, 2025 08:15 HKT/SGT
|
|
|
Saudi Electricity Company Reports 22% Net Profit Growth in Q2 2025
Aug 11, 2025 06:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
